Scholars Central

OtherPublished 12 Jul 2016

Personalized medicine in colorectal cancer: the evidence so far

Authors: Avinash Gupta, Wasir Saka, David J Kerr

Clinical Investigation

Volume 2 · Issue 10 · Pages 1013–102

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Current treatment continues to mostly be determined by stratifying patients into fairly broad groups, according to prognosis based on clinicopathological and histopathological staging. Conventional chemotherapy remains the mainstay of systemic treatment, with no established means of predicting response to treatment. However, greater understanding of the molecular biology underlying colorectal cancer, and the manner in which this influences prognosis and response to systemic therapy is increasingly well understood. In the future, key genetic changes in an individual patient’s cancer could potentially be used to more accurately predict the risk of relapse following surgery and the likely response to systemic therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Avinash Gupta”
  • BylineArticles whose byline prints “Wasir Saka”
  • BylineArticles whose byline prints “David J Kerr”